Catecholaminergic polymorphic ventricular tachycardia primary prevention

Revision as of 15:17, 23 July 2020 by Mounika (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Catecholaminergic polymorphic ventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Catecholaminergic polymorphic ventricular tachycardia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Exercise Stress Testing

Genetic Testing

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Implantable Cardioverter-Defibrillator

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Catecholaminergic polymorphic ventricular tachycardia primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Catecholaminergic polymorphic ventricular tachycardia primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Catecholaminergic polymorphic ventricular tachycardia primary prevention

CDC on Catecholaminergic polymorphic ventricular tachycardia primary prevention

Catecholaminergic polymorphic ventricular tachycardia primary prevention in the news

Blogs on Catecholaminergic polymorphic ventricular tachycardia primary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Catecholaminergic polymorphic ventricular tachycardia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mounika Reddy Vadiyala, M.B.B.S.[2]

Overview

There are no established measures for the primary prevention of catecholaminergic polymorphic ventricular tachycardia. However, episodes of syncope and sudden cardiac arrest can be prevented with lifestyle modifications, holter monitoring and compliance with medical therapy.

Primary Prevention

There are no established measures for the primary prevention of catecholaminergic polymorphic ventricular tachycardia.
However, there are preventive measures for episodes of catecholaminergic polymorphic ventricular tachycardia, which include:

  • Lifestyle modifications:[1]
    1. Limit or avoid competitive sports
    2. Limit or avoid strenuous exercises
    3. Limit exposure to stressful environments
  • Holter monitoring: It helps in keeping the heart-rate within a safe range during physical activity.
  • Compliance with medical therapy.
  • Follow-up visits with a cardiologist every six to twelve months to monitor the efficacy of therapy.

References

  1. Priori, Silvia G.; Blomström-Lundqvist, Carina; Mazzanti, Andrea; Blom, Nico; Borggrefe, Martin; Camm, John; Elliott, Perry Mark; Fitzsimons, Donna; Hatala, Robert; Hindricks, Gerhard; Kirchhof, Paulus; Kjeldsen, Keld; Kuck, Karl-Heinz; Hernandez-Madrid, Antonio; Nikolaou, Nikolaos; Norekvål, Tone M.; Spaulding, Christian; Van Veldhuisen, Dirk J. (2015). "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". European Heart Journal. 36 (41): 2793–2867. doi:10.1093/eurheartj/ehv316. ISSN 0195-668X.

Template:WH Template:WS